Last Price$1.3(9.4%)
Market Cap$8,155.2K
LTM Research & Development Expenses (R&D)
$99.5K
YoY Growth
-66.0%
3Y CAGR
-52.8%
5Y CAGR
-49.3%
Stock quality & Intrinsic value
4/10
297.3% undervalued
Predictive Oncology Inc. Research & Development Expenses (R&D)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Expenses (R&D) | $0.0 | $0.0 | $0.0 | $0.0 | $15.0K | $235.1K | $394.0K | $261.0K | $406.0K | $289.0K | $1,861.1K | $2,960.1K | $2,351.7K | $315.9K | $320.3K | $188.3K |
Overvalued or undervalued?
Check the intrinsic value for POAI
and see if it's the right time to invest.
Predictive Oncology Inc. (POAI) Research & Development Expenses (R&D) comparison analysis
General
LTM Research & Development Expenses (R&D)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Predictive Oncology Inc.POAI
$99.5K
(66.0%)
(52.8%)
(49.3%)
Median Peer Set
$379.7M
3.4%
8.7%
8.8%
Becton, Dickinson and CompanyBDX
$1,243.0M
2.4%
(3.0%)
3.0%
Intuitive Surgical, Inc.ISRG
$1,145.3M
14.7%
19.5%
15.5%
Alcon Inc.ALC
$876.0M
4.4%
1.3%
6.0%
Baxter International Inc.BAX
$673.0M
0.9%
8.0%
2.5%
AptarGroup, Inc.ATR
$440.6M
(22.1%)
1.9%
7.4%
ResMed Inc.RMD
$318.8M
4.8%
10.2%
10.1%
Hologic, Inc.HOLX
$266.3M
(7.0%)
(2.8%)
2.1%
Masimo CorporationMASI
$222.8M
27.2%
17.5%
19.0%
The Cooper Companies, Inc.COO
$155.1M
12.9%
18.7%
12.3%
West Pharmaceutical Services, Inc.WST
$69.1M
1.0%
9.4%
12.2%
POAI key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 (98.2%) | 0.1 33,454.5% | 0.2 95.3% | 0.5 148.0% | 1.0 103.3% | 0.7 (31.2%) | 0.5 (30.2%) | 0.7 43.4% | 1.4 115.6% | 1.4 (0.0%) | 1.3 (11.3%) | 1.4 13.4% | 1.5 6.0% | 1.8 18.2% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.2 | 0.4 | 0.3 | 0.2 | 0.1 | 0.4 | 0.5 | 0.4 | 0.5 | 0.5 | 0.6 |
% margin | 0.0 0.0% | 0.0 55.5% | 0.0 51.4% | 0.0 42.0% | 0.1 31.9% | 0.3 59.5% | 0.6 59.5% | 0.4 53.5% | 0.3 60.2% | 0.5 77.4% | 1.0 70.5% | 0.9 62.3% | 0.8 64.3% | 0.9 65.7% | 1.0 66.4% | 1.1 64.3% |
| Operating Expenses | 1.7 | 2.5 | 1.2 | 4.1 | 7.2 | 9.2 | 7.0 | 4.8 | 6.8 | 8.3 | 8.9 | 14.7 | 13.3 | 14.4 | 16.3 | 15.1 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.4 | 0.3 | 0.4 | 0.3 | 1.9 | 3.0 | 2.4 | 0.3 | 0.3 | 0.2 |
| Selling, General & Administrative Expenses (SG&A) | 1.4 | 2.0 | 2.1 | 4.1 | 7.2 | 9.2 | 7.0 | 4.8 | 5.6 | 8.3 | 7.0 | 11.7 | 10.9 | 11.7 | 12.5 | 10.9 |
% margin | (1.7) 0.0% | (2.4) (15,528.1%) | (1.2) (418,616.7%) | (4.1) (4,248.3%) | (7.2) (3,792.8%) | (8.9) (1,907.1%) | (6.5) (679.7%) | (4.4) (672.4%) | (6.5) (1,429.6%) | (7.7) (1,183.0%) | (7.9) (556.9%) | (13.8) (975.8%) | (0.7) (53.2%) | (13.5) (948.2%) | (15.3) (1,014.2%) | (13.9) (782.1%) |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest Expense | 0.1 | 0.1 | 0.1 | 0.2 | 0.3 | 0.6 | 0.4 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.7 | 0.0 |
| Pre-tax Income | 0.0 | (1.8) | (1.4) | (4.5) | (7.4) | (9.4) | (6.8) | (4.8) | (6.5) | (7.7) | (10.1) | (19.4) | (25.9) | (20.3) | (25.7) | (14.0) |
% effective tax rate | 0.1 0.0% | 0.4 (25.4%) | 0.0 0.0% | 0.2 (5.1%) | 0.3 (3.5%) | 0.6 (6.8%) | 0.4 (5.5%) | 0.0 0.0% | 0.0 0.0% | 0.1 (0.7%) | (2.2) 22.1% | 8.2 (42.1%) | 11.8 (45.7%) | (0.7) 3.3% | 10.5 (40.7%) | 0.0 0.0% |
% margin | (1.8) 0.0% | (2.9) (18,378.5%) | (1.4) (469,690.6%) | (4.5) (4,643.0%) | (7.4) (3,931.8%) | (9.4) (2,009.4%) | (6.8) (718.1%) | (4.8) (732.1%) | (6.5) (1,429.6%) | (7.7) (1,183.0%) | (10.1) (714.5%) | (27.6) (1,952.2%) | (37.7) (3,010.7%) | (19.7) (1,383.6%) | (36.2) (2,405.1%) | (14.0) (785.6%) |
| EPS | (65,282.52) | (96,407.67) | (36,559.70) | (52,786.81) | (26,794.78) | (16,051.71) | (11,057.55) | (4,601.85) | (462.31) | (243.50) | (157.40) | (192.02) | (63.10) | (7.16) | (9.92) | (3.48) |
| Diluted EPS | (65,282.52) | (96,407.67) | (36,559.70) | (52,786.81) | (26,794.78) | (16,051.71) | (11,057.55) | (4,601.85) | (462.31) | (243.50) | (157.40) | (192.02) | (63.10) | (7.16) | (9.92) | (3.48) |
% margin | (1.7) 0.0% | (2.8) (17,857.6%) | (1.2) (417,773.3%) | (4.3) (4,401.3%) | (7.2) (3,793.9%) | (8.8) (1,871.6%) | (6.4) (671.8%) | (4.3) (660.4%) | (6.4) (1,411.5%) | (6.0) (913.5%) | (7.7) (546.4%) | (12.4) (879.4%) | (11.5) (915.0%) | (12.1) (853.9%) | (14.0) (926.9%) | (13.2) (740.5%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Predictive Oncology Inc.'s Research & Development Expenses (R&D)?
As of today, Predictive Oncology Inc.'s last 12-month Research & Development Expenses (R&D) is $99.5K, based on the financial report for Sep 30, 2024 (Q3’2024).
2) What is Predictive Oncology Inc.'s Research & Development Expenses (R&D) growth rate?
Over the last year, Predictive Oncology Inc.'s Research & Development Expenses (R&D) growth was (66.0%). The average annual Research & Development Expenses (R&D) growth rates for Predictive Oncology Inc. have been (62.6%) over the past three years, (49.3%) over the past five years.
3) Is Predictive Oncology Inc.'s Research & Development Expenses (R&D) growth rate Good?
Over the last year, Predictive Oncology Inc.'s Research & Development Expenses (R&D) growth was (66.0%), which is lower than industry growth of 0.0%. It indicates that Predictive Oncology Inc.'s Research & Development Expenses (R&D) growth is Good.